Atlas Wealth Partners LLC Decreases Stock Holdings in Johnson & Johnson $JNJ

Atlas Wealth Partners LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,127 shares of the company’s stock after selling 425 shares during the quarter. Johnson & Johnson comprises about 0.6% of Atlas Wealth Partners LLC’s investment portfolio, making the stock its 26th largest holding. Atlas Wealth Partners LLC’s holdings in Johnson & Johnson were worth $478,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $218,000. Smart Money Group LLC raised its position in shares of Johnson & Johnson by 6.5% in the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after purchasing an additional 407 shares during the last quarter. Bolthouse Investments LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $234,000. Finally, Sierra Ocean LLC raised its position in shares of Johnson & Johnson by 10.9% in the 1st quarter. Sierra Ocean LLC now owns 2,264 shares of the company’s stock valued at $376,000 after purchasing an additional 222 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Bank of America increased their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a report on Monday, October 20th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Finally, Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $186.89 on Wednesday. The stock has a market capitalization of $450.27 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The firm’s 50 day simple moving average is $183.64 and its 200-day simple moving average is $168.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.